WRF
UROV

Waddell & Reed Financial’s Urovant Sciences Ltd. UROV Stock Holding History

Waddell & Reed Financial’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-35,000
Closed -$420K – 574
2018
Q3 		$420K Buy
+35,000
New +$414K ﹤0.01% 536

Other funds holding UROV

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Waddell & Reed Financial's UROV Position: Q4 2018 in Review

Waddell & Reed Financial sold out of Urovant Sciences Ltd. (UROV) in Q4 2018, closing a stake of 35,000 shares — an estimated $420K sold.

Waddell & Reed Financial first reported a position in UROV in Q3 2018 and held it in 1 quarter. The position peaked at $420K in Q3 2018. 26 funds tracked by Wall St. Rank hold UROV as of Q4 2018.

  • Waddell & Reed Financial reported no remaining Urovant Sciences Ltd. position as of Q4 2018 after selling out during the quarter.
  • Waddell & Reed Financial sold 35,000 Urovant Sciences Ltd. shares in Q4 2018, an estimated $420K.
  • Waddell & Reed Financial first reported a position in Urovant Sciences Ltd. in Q3 2018 and held it in 1 quarter.
  • Waddell & Reed Financial's Urovant Sciences Ltd. position peaked at $420K in Q3 2018.
  • 26 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q4 2018.

Based on Waddell & Reed Financial's 13F filing for Q4 2018, filed 14 Feb 2019.